LEGN
Legend Biotech Corp
$35.87
-1.13%
$6.6B
No data for this timeframe.
Vol
Market Cap$6.6B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (87%)
Inst. Holders50 funds
Inst. Value$902.4M
Inst. Activity15 buys / 6 sells
Insider Activity0B / 1S
Insider Net $-$87.1K
SEC Reports7
Press Releases5
Recent Activity
Jun 2, 2026
SEC
Legend Biotech announced initial Phase 1 data for LB2501, a first-in-class in vivo CD19/CD20 dual-targeting CAR-T therap
6-K — Impact 7/10
Jun 1, 2026
SEC
Legend Biotech presented first-in-human Phase 1 data for LB2102 (DLL3-targeted CAR-T) in solid tumors at ASCO 2026, show
6-K — Impact 6/10
May 21, 2026
SEC
Legend Biotech announced it will present preliminary Phase 1 data for LB2102 (DLL3-targeted CAR-T in solid tumors) as a
6-K — Impact 4/10
Mar 25, 2026
Insider
Huang Ying sold 9,936 shares
Chief Executive Officer @ $8.77 ($87.1K)
Inst.
Point72 Asset Management, L.P. — ADD
3,886,017 shares ($70.3M)
Inst.
Hudson Bay Capital Management — ADD
876,351 shares ($15.9M)
Jun 14, 2026
Press
Legend Biotech presented first-in-human proof-of-concept data for LB2501, an in vivo CD19/CD20 dual-targeting CAR-T ther
Impact 7/10
Jun 14, 2026
fda
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
<p align="justify">BRIDGEWATER, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation
Price Targets
$57.59
+60.6% upside
Strong Buy
Current $35.87
Low $27.00
Median $60.00
High $86.00
15 analysts
$27.00
$86.00
Analyst Ratings
7Strong Buy
13Buy
3Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 3, 2026 | UBS | MAINTAIN | Buy → Buy |
| Jun 3, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| May 18, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 13, 2026 | TD Cowen | MAINTAIN | Hold → Hold |
| May 13, 2026 | Morgan Stanley | MAINTAIN | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.28 ▲ +411.1% | $0.28 — $0.28 | 141% YoY | 1 |
| Next Q | $0.10 ▲ +1100.0% | $0.10 — $0.10 | 145% YoY | 1 |
| Current FY | $0.28 ▲ +351.6% | $0.28 — $0.28 | 117% YoY | 1 |
| Next FY | $1.30 ▲ +16.1% | $1.06 — $1.56 | 346% YoY | 4 |
Latest Reports
BULLISH
Press
7/10
Legend Biotech presented first-in-human proof-of-concept data for LB2501, an in vivo CD19/CD20 dual-targeting CAR-T ther
Jun 14, 2026
BULLISH
6-K
7/10
Legend Biotech announced initial Phase 1 data for LB2501, a first-in-class in vivo CD19/CD20 dual-targeting CAR-T therap
Jun 2, 2026
BULLISH
6-K
6/10
Legend Biotech presented first-in-human Phase 1 data for LB2102 (DLL3-targeted CAR-T) in solid tumors at ASCO 2026, show
Jun 1, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $464.9M | — |
| BlackRock, Inc. | $84.7M | — |
| Point72 Asset Management, L.P. | $70.3M | ADD |
| Artisan Partners Limited Partnership | $40.8M | — |
| TWO SIGMA INVESTMENTS, LP | $34.2M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 25, 2026 | Huang Ying | SELL | $87.1K |
50 institutional holders with $902.4M total value (49,895,190 shares) as of 2026-Q1. Top holders: FMR, BlackRock,, Point72. Net buying activity: 15 institutions added/increased vs 6 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 25,696,740 | $464.9M | 51.5% | — |
| 2 | BlackRock, Inc. | 4,684,543 | $84.7M | 9.4% | — |
| 3 | Point72 Asset Management, L.P. | 3,886,017 | $70.3M | 7.8% | ADD +39.5% |
| 4 | Artisan Partners Limited Partnership | 2,254,488 | $40.8M | 4.5% | — |
| 5 | TWO SIGMA INVESTMENTS, LP | 1,890,396 | $34.2M | 3.8% | ADD +46.2% |
| 6 | STATE STREET CORP | 1,498,372 | $27.1M | 3.0% | ADD +31.0% |
| 7 | GOLDMAN SACHS GROUP INC | 1,464,112 | $26.5M | 2.9% | — |
| 8 | Hudson Bay Capital Management LP | 876,351 | $15.9M | 1.8% | ADD +52.4% |
| 9 | Capital International Investors | 647,850 | $11.7M | 1.3% | TRIM -31.2% |
| 10 | MORGAN STANLEY | 603,247 | $10.9M | 1.2% | ADD +25.0% |
| 11 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 574,898 | $10.4M | 1.2% | — |
| 12 | RENAISSANCE TECHNOLOGIES LLC | 521,800 | $9.4M | 1.0% | ADD +29.5% |
| 13 | CITADEL ADVISORS LLC | 516,980 | $9.4M | 1.0% | — |
| 14 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 406,901 | $7.4M | 0.8% | DOUBLED +343.6% |
| 15 | SEI INVESTMENTS CO | 324,921 | $5.9M | 0.7% | DOUBLED +215.4% |
| 16 | MARSHALL WACE, LLP | 287,123 | $5.2M | 0.6% | TRIM -62.0% |
| 17 | Legal & General Group Plc | 233,868 | $4.2M | 0.5% | — |
| 18 | HSBC HOLDINGS PLC | 221,475 | $4.0M | 0.4% | TRIM -49.6% |
| 19 | Woodline Partners LP | 205,870 | $3.7M | 0.4% | — |
| 20 | Trexquant Investment LP | 191,993 | $3.5M | 0.4% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Point72 Asset Management, L.P. | ADD | 2,784,806 | 3,886,017 | +39.5% | $70.3M | 2026-Q1 |
| Hudson Bay Capital Management LP | ADD | 575,000 | 876,351 | +52.4% | $15.9M | 2026-Q1 |
| Capital International Investors | TRIM | 941,600 | 647,850 | -31.2% | $11.7M | 2026-Q1 |
| MORGAN STANLEY | ADD | 482,550 | 603,247 | +25.0% | $10.9M | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 402,800 | 521,800 | +29.5% | $9.4M | 2026-Q1 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | DOUBLED | 91,725 | 406,901 | +343.6% | $7.4M | 2026-Q1 |
| SEI INVESTMENTS CO | DOUBLED | 103,022 | 324,921 | +215.4% | $5.9M | 2026-Q1 |
| MARSHALL WACE, LLP | TRIM | 755,953 | 287,123 | -62.0% | $5.2M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | TRIM | 287,529 | 177,862 | -38.1% | $3.2M | 2026-Q1 |
| MUTUAL OF AMERICA CAPITAL MANAGEMENT LLC | ADD | 80,363 | 138,046 | +71.8% | $2.5M | 2026-Q1 |
| Mitsubishi UFJ Asset Management Co., Ltd. | ADD | 75,078 | 96,781 | +28.9% | $1.8M | 2026-Q1 |
| Rockefeller Capital Management L.P. | DOUBLED | 56 | 83,178 | +148432.1% | $1.5M | 2026-Q1 |
| NOMURA HOLDINGS INC | DOUBLED | 30,429 | 80,000 | +162.9% | $1.4M | 2026-Q1 |
| GROUP ONE TRADING LLC | ADD | 39,976 | 50,910 | +27.4% | $921.0K | 2026-Q1 |
| FEDERATED HERMES, INC. | ADD | 16,500 | 28,000 | +69.7% | $506.5K | 2026-Q1 |
| PNC FINANCIAL SERVICES GROUP, INC. | ADD | 11,134 | 20,719 | +86.1% | $374.8K | 2026-Q1 |
| CAISSE DE DEPOT ET PLACEMENT DU QUEBEC | TRIM | 30,778 | 16,216 | -47.3% | $293.3K | 2026-Q1 |
| BANQUE PICTET & CIE SA | TRIM | 14,502 | 5,159 | -64.4% | $93.3K | 2026-Q1 |
| CWM, LLC | DOUBLED | 29 | 1,817 | +6165.5% | $32.9K | 2026-Q1 |
| DANSKE BANK A/S | NEAR_EXIT | 7,600 | 900 | -88.2% | $16.3K | 2026-Q1 |
| FIFTH THIRD BANCORP | DOUBLED | 136 | 319 | +134.6% | $5.8K | 2026-Q1 |
| Point72 Asset Management, L.P. | NEW | — | 2,784,806 | — | $60.5M | 2025-Q4 |
| ALLIANCEBERNSTEIN L.P. | NEW | — | 1,517,067 | — | $33.0M | 2025-Q4 |
| STATE STREET CORP | ADD | 1,157,122 | 1,516,368 | +31.0% | $33.0M | 2025-Q4 |
| MARSHALL WACE, LLP | DOUBLED | 17,872 | 755,953 | +4129.8% | $16.4M | 2025-Q4 |
1 unique insiders with 1 transactions. Net insider value: -$87.1K ($0.00 bought, $87.1K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 25, 2026 | Huang Ying | Chief Executive Officer | SELL | 9,936 | $8.77 | $87.1K |
7 SEC filing reports analyzed. Sentiment: 5 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 5.7/10.
BULLISH
6-K
7/10
Legend Biotech announced initial Phase 1 data for LB2501, a first-in-class in vivo CD19/CD20 dual-ta
Jun 2, 2026
BULLISH
6-K
6/10
Legend Biotech presented first-in-human Phase 1 data for LB2102 (DLL3-targeted CAR-T) in solid tumor
Jun 1, 2026
NEUTRAL
6-K
4/10
Legend Biotech announced it will present preliminary Phase 1 data for LB2102 (DLL3-targeted CAR-T in
May 21, 2026
BULLISH
6-K
7/10
Legend Biotech reported Q1 2026 results with total revenue of $305.1M, up 56% YoY from $195.0M, driv
May 12, 2026
BULLISH
PRESS-RELEASE
7/10
Legend Biotech reported Q1 2026 revenue of $305.1M (vs $306.5M consensus, slight miss) and EPS of -$
May 12, 2026
NEUTRAL
PRESS-RELEASE
2/10
Legend Biotech announced a conference call to discuss Q1 2026 financial results on May 12, 2026. No
Apr 28, 2026
BULLISH
6-K
7/10
Legend Biotech reported preliminary net trade sales of $597 million for CARVYKTI® in Q1 2026, based
Apr 14, 2026
BULLISH
7/10
Legend Biotech presented first-in-human proof-of-concept data for LB2501, an in vivo CD19/CD20 dual-
Jun 14, 2026
BULLISH
7/10
Legend Biotech announced promising Phase 1 data for LB2501, an in vivo CD19/CD20 dual-targeting CAR-
Jun 2, 2026
BULLISH
6/10
Legend Biotech presented early clinical data for LB2102 (DLL3 CAR-T) in SCLC/LCNEC at ASCO, showing
Jun 1, 2026
BULLISH
7/10
Legend Biotech announced multiple ASCO 2026 presentations, including a rapid oral presentation of pr
May 21, 2026
BULLISH
8/10
Legend Biotech reported strong Q4 and full-year 2025 financial results driven by CARVYKTI® sales, wi
Mar 10, 2026
Current analyst consensus: Strong Buy (87% buy). Based on 23 analysts: 7 strong buy, 13 buy, 3 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$57.59 mean target
+60.6% upside
Strong Buy (1.60)
$27.00 Low
$86.00 High
| Metric | Value |
|---|---|
| Current Price | $35.87 |
| Target Low | $27.00 |
| Target Mean | $57.59 |
| Target Median | $60.00 |
| Target High | $86.00 |
| # Analysts | 15 |
| Recommendation | Strong Buy (1.60) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.28 | $0.28 | $0.28 | 141.2% | +411.1% | 1↑ 0↓ | $0.4B | 42.3% | 1 |
| Next Q 2026-09-30 |
$0.10 | $0.10 | $0.10 | 145.4% | +1100.0% | 1↑ 0↓ | $0.4B | 35.7% | 1 |
| Current FY 2026-12-31 |
$0.28 | $0.28 | $0.28 | 117.5% | +351.6% | 1↑ 0↓ | $1.4B | 39.9% | 1 |
| Next FY 2027-12-31 |
$1.30 | $1.06 | $1.56 | 345.6% | +16.1% | 1↑ 0↓ | $1.8B | 26.9% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.280 | |
| 7d ago | $0.280 | |
| 30d ago | $-0.090 | +0.370 |
| 60d ago | $-0.090 | +0.370 |
| 90d ago | $0.053 | +0.227 |
8 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 3, 2026 | UBS | MAINTAIN | Buy | Buy |
| Jun 3, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| May 18, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 13, 2026 | TD Cowen | MAINTAIN | Hold | Hold |
| May 13, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| May 13, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Apr 21, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 15, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 11, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Mar 11, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Feb 4, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Jan 22, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 22, 2026 | TD Cowen | DOWNGRADE | Buy | Hold |
| Jan 20, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Jan 7, 2026 | Oppenheimer | INITIATE | — | Outperform |
| Dec 17, 2025 | Cantor Fitzgerald | MAINTAIN | Overweight | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 7 | 13 | 3 | 0 | 0 | 87% | |
| May 1, 2026 | 7 | 14 | 3 | 0 | 0 | 88% | |
| Apr 1, 2026 | 7 | 14 | 3 | 0 | 0 | 88% | |
| Mar 1, 2026 | 7 | 14 | 4 | 0 | 0 | 84% | |
| Feb 1, 2026 | 7 | 15 | 3 | 0 | 0 | 88% | |
| Jan 1, 2026 | 6 | 16 | 2 | 0 | 0 | 92% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 14, 2026
fda
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
<p align="justify">BRIDGEWATER, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader
Jun 10, 2026
short_volume
Short Volume: LEGN — 61.9% short (0.5M / 0.8M)
Short: 509,845 | Exempt: 50 | TRF Vol: 823,402 | Short Ratio: 61.9% | Off-exchange volume (dark pool + OTC)
Jun 9, 2026
short_volume
Short Volume: LEGN — 69.3% short (0.6M / 0.9M)
Short: 629,442 | Exempt: 0 | TRF Vol: 908,801 | Short Ratio: 69.3% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
fda
Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)
<p align="justify">BRIDGEWATER, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech or the Company), a
Jun 1, 2026
fda
Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026
<p align="justify">BRIDGEWATER, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech or the Company),
May 27, 2026
short_volume
Short Volume: LEGN — 56.6% short (0.3M / 0.5M)
Short: 292,603 | Exempt: 1 | TRF Vol: 516,866 | Short Ratio: 56.6% | Off-exchange volume (dark pool + OTC)
May 22, 2026
short_volume
Short Volume: LEGN — 68.2% short (0.5M / 0.8M)
Short: 519,568 | Exempt: 15 | TRF Vol: 762,243 | Short Ratio: 68.2% | Off-exchange volume (dark pool + OTC)
May 21, 2026
fda
Legend Biotech Announces Presentations at ASCO 2026
<p align="justify">SOMERSET, N.J., May 21, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech or the Company), a glo
May 20, 2026
short_volume
Short Volume: LEGN — 62.9% short (0.4M / 0.7M)
Short: 419,209 | Exempt: 0 | TRF Vol: 666,709 | Short Ratio: 62.9% | Off-exchange volume (dark pool + OTC)
May 14, 2026
short_volume
Short Volume: LEGN — 63.0% short (0.7M / 1.1M)
Short: 694,945 | Exempt: 183 | TRF Vol: 1,102,491 | Short Ratio: 63.0% | Off-exchange volume (dark pool + OTC)
May 13, 2026
short_volume
Short Volume: LEGN — 67.8% short (0.7M / 1.1M)
Short: 717,596 | Exempt: 0 | TRF Vol: 1,058,979 | Short Ratio: 67.8% | Off-exchange volume (dark pool + OTC)
May 12, 2026
earnings
Legend Biotech Reports First Quarter 2026 Results and Recent Highlights
<p align="justify">SOMERSET, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in c
May 12, 2026
earnings_calendar
LEGN Q1 2026 Earnings Before Market Open — 2026-05-12
May 7, 2026
short_volume
Short Volume: LEGN — 56.8% short (0.3M / 0.6M)
Short: 314,176 | Exempt: 0 | TRF Vol: 552,756 | Short Ratio: 56.8% | Off-exchange volume (dark pool + OTC)
May 5, 2026
short_volume
Short Volume: LEGN — 56.1% short (1.8M / 3.2M)
Short: 1,766,194 | Exempt: 409 | TRF Vol: 3,150,331 | Short Ratio: 56.1% | Off-exchange volume (dark pool + OTC)